Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 84Lymphoma, Follicular 46Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 21Lymphoma, B-Cell 17Recurrence 13Neoplasms 11Leukemia 7Leukemia, B-Cell 6Burkitt Lymphoma 5Leukemia, Hairy Cell 4Neoplasm, Residual 3Melanoma 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Disease 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1

Interventions

pembrolizumab 92Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 24Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × obinutuzumab × Clear all
NCT05894447 2024-04-12

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Weill Medical College of Cornell University

Phase 1 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡